Brief: Denali Therapeutics Q4 Operating Income USD -129.846 Million
27/02/2025 21:01
Feb 27 (Reuters) - Denali Therapeutics Q4 basic EPS USD -0.67. Q4 net income USD -114.753 million Q4 operating expenses USD 129.846 million Q4 pretax profit USD -114.685 million
Recent news on Denali Therapeutics
See all newsDenali Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Denali Therapeutics Q2 net loss widens as AVLAYAH launch costs rise
Biogen's Alzheimer's drug lowers toxic protein, but results were mixed
U.S. STOCKS ON THE MOVE-Sweetgreen, Dell Technologies, Peloton Interactive
U.S. STOCKS ON THE MOVE-IMAX, Novo Nordisk, PC makers